As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...
By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong growth for 2026 on Wednesday on the back of ...
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...
Eli Lilly & Co. provided an upbeat sales forecast for the year Wednesday as strong demand for its weight loss drug cemented its position at the top of the obesity market.
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their ...
The target action date for orforglipron is now April 10.
The stock price has climbed in the triple digits over three years.
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results